Recent news on Epoprostenol

New Strategies for Pulmonary Arterial Hypertension: Evaluation and ...  -  Apr 23, 2007
Medscape (subscription)Drugs attempting to correct the prostacyclin deficiency underlying PAH are the prostanoids (epoprostenol, treprostinil, and iloprost).

Intravenous Treprostinil Linked to Higher Rate of Bloodstream ...  -  Mar 2, 2007
Medscape (subscription)Both medications are administered primarily at home; benefits of treprostinil over the older drug epoprostenol include a longer half-life (4 hours vs 3-6

United Therapeutics Announces Pulmonary Hypertension Opinion ...  -  Mar 8, 2007
Drug Newswire (press release),...among patients treated with intravenous epoprostenol and intravenous treprostinil for pulmonary arterial hypertension, United States 2004 - 2006".

Intravenous treprostinil linked to increased rates of bloodstream ...  -  Mar 2, 2007
Therapeutics Daily (subscription) (press release),Only two prostanoids are approved for use in the US, epoprostenol (Flolan) and treprostinil. The CDC supervised a retrospective investigation for 2003 to

Study Raises Questions For United Therapeutics  -  Feb 26, 2007
Washington Post,...compared with patients given another type of prostacyclin called epoprostenol, marketed by GlaxoSmithKline under the trade name Flolan.

United Therapeutics Volume Heavy on Data  -  Feb 26, 2007
Houston Chronicle,...compared with patients given another prostacyclin called epoprostenol, marketed by GlaxoSmithKline PLC under the trade name Flolan.

United Therapeutics Volume Heavy on Data  -  Feb 26, 2007
Forbes,...with patients given another prostacyclin called epoprostenol, marketed by GlaxoSmithKline (nyse: GSK - news - people ) PLC under the trade name Flolan.

Improved Long-Term Outcome With Remodulin Reported in European ...  -  Feb 1, 2007
PR Newswire (press release),...(Eur Respir J 2006:1195-1203); and Rapid Switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.

Improved Long-Term Outcome With Remodulin Reported in European ...  -  Feb 1, 2007
DG NewsIn addition, results reported this month in the Journal of Cardiovascular Pharmacology demonstrate that rapid transition from intravenous epoprostenol to

Specialty Infusion Brings New Challenges, Solutions to Payers  -  Feb 12, 2007
Atlantic Information Services, Inc.,...under which drugs such as Remicade (infliximab), Novantrone (mitoxantrone), Flolan (epoprostenol sodium) and Remodulin (treprostinil sodium) fall.

Researchers Explore Rare Lung Disorder  -  Feb 6, 2007
Journal of American Medical Association (subscription),Current treatments include anticoagulants, calcium channel blockers, and continuous intravenous epoprostenol. Two other medications received recent FDA

Carbon dioxide embolism induced by endoscopic saphenous vein ...  -  Dec 7, 2006
The Journal of Thoracic and Cardiovascular Surgery...echocardiographic diagnosis of carbon dioxide embolism during minimally invasive saphenous vein harvesting and treatment with inhaled epoprostenol.

Darusentan Data to Be Presented at AHA 2006 -- Chicago  Nov 6, 2006
...have entered into a global PAH collaboration in which Myogen has marketing and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol sodium) for ... -Genetic Engineering News (press release), Pulmonary Hypertension  Sep 22, 2006
Oral and inhaled treatments may also be used. One of the most effective medications for pulmonary hypertension is epoprostenol. ... -WSOCtv.com

Exercise and Respiratory Training Ease Life With Pulmonary ...  Sep 19, 2006
Baseline drug therapy included Tracleer (bosentan), Revatio (sildenafil), Ventavis (iloprost), Flolan (epoprostenol), beraprost, and calcium channel blockers. ... -MedPage Today

Myogen to Present at the UBS Global Life Sciences Conference  Sep 20, 2006
...have entered into a global PAH collaboration in which Myogen has marketing and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol sodium) for ... -Business Wire

Carbon dioxide embolism induced by endoscopic saphenous vein ...  -  12 Dec 2006
The Journal of Thoracic and Cardiovascular Surgery...echocardiographic diagnosis of carbon dioxide embolism during minimally invasive saphenous vein harvesting and treatment with inhaled epoprostenol.

Myogen Reports 2006 Second Quarter Results  Aug 7, 2006
...and Myogen enteredinto an agreement whereby Myogen will be responsible for the marketingand distribution of GSK's Flolan (epoprostenol sodium), a life ... -Finanzen.net

Myogen Reports 2006 Second Quarter Results  Aug 7, 2006
...and Myogen entered into an agreement whereby Myogen will be responsible for the marketing and distribution of GSK's Flolan (epoprostenol sodium), a life-saving ... -PharmaLive.com



Accredo Health Signs Pharmacy Agreement for Flolan  16 May 2006
2006 - (NewsRx.com) -- Accredo Health Group, Inc., announced an exclusive 5-year agreement as the sole specialty pharmacy for Flolan (epoprostenol sodium), a ... - Therapeutics Daily (subscription)

Myogen Reports 2006 First Quarter Results  May 8, 2006
...and Myogen entered into an agreement whereby Myogen will be responsible for the marketing and distribution of GSK's Flolan (epoprostenol sodium), a life-saving ... - Genetic Engineering News

Myogen Reports Results for the Integrated Analysis of ARIES-1 and ...  May 3, 2006
...have entered into a global PAH collaboration in which Myogen has distribution and marketing rights to GlaxoSmithKline's Flolan (epoprostenol sodium) in the ... - PharmaLive.com

Myogen to Announce 2006 First Quarter Results on May 8, 2006  Apr 21, 2006
...have entered into a global PAH partnership in which Myogen has marketing and distribution rights to GlaxoSmithKline's Flolan (epoprostenol sodium) in the ... - International News Service

Accredo Health Signs Exclusive Five-Year Specialty Pharmacy ...  Apr 17, 2006
...largest specialty pharmacy operation, today announced an exclusive five-year agreement as the sole specialty pharmacy for Flolan(R) (epoprostenol sodium), a ... - International News Service





News For Your Web Site  11 Apr 2006
...have entered into a global PAH partnership in which Myogen has distribution and marketing rights to GlaxoSmithKline's Flolan (epoprostenol sodium) in the ... - dBusinessNews Denver

PAH: market ripe for expansion as big pharma interest increases  Mar 27, 2006
...reached $636 million in 2004, driven mainly by sales of Actelion's Tracleer (bosentan) and GlaxoSmithKline's (GSK's) Flolan (epoprostenol), which generated ... - Pharmaceutical Business Review

Lung transplant could give area woman a second chance  Mar 26, 2006
She carries an infusion pump to administer the drug Epoprostenol continuously through a shunt in her chest, which helps open up the blood vessels in the lungs ... - Longmont Daily Times-Call

PAH: Market ripe for expansion as big pharma interest increases  Mar 23, 2006
...reached $636million in 2004, driven mainly by sales of Actelion's Tracleer (bosentan) and GlaxoSmithKline's (GSKs) Flolan (epoprostenol), which generated sales ... - PharmaLive.com

GSK and Myogen forge cardio partnership  Mar 7, 2006
...have entered into a distribution agreement whereby Myogen will be responsible for the marketing and distribution of GSK's Flolan (epoprostenol sodium), which ... - Pharmaceutical Business Review

Imperial School of Medicine, National Heart and Lung Institute ...  Mar 9, 2006
...associated with congenital heart or connective tissue disease) started bosentan with or without concomitant intravenous epoprostenol or subcutaneous ... - AJRCCM (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional